Computer-aided selection of potential antihypertensive compounds with dual mechanism of action

Journal of Medicinal Chemistry

Volumn 46, Issue 15, 2003, Pages 3326-3332

  Lagunin, Alexey A ^a   Gomazkov, Oleg A ^a   Filimonov, Dmitrii A ^a   Gureeva, Tatyana A ^a   Dilakyan, Elvira A ^a   Kugaevskaya, Elena V ^a   Elisseeva, Yulia E ^a   Solovyeva, Nina I ^a   Poroikov, Vladimir V ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; MEMBRANE METALLOENDOPEPTIDASE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; COMPUTER PROGRAM; DATA BASE; DRUG MECHANISM; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PREDICTION; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BRAIN; CATTLE; COMPUTERS; DATABASES, FACTUAL; HUMANS; KIDNEY CORTEX; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; PROBABILITY; RATS;

EID: 0038155205     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021089h     Document Type: Article

References (46)

1. Uchida, W.; Shibasaki, K.; Matsuda, Y.; Asano, M.; Takenaka, T. Cardiovascular effects of YM-16151-4: a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent in rats and dogs. J. Cardiovasc. Pharmacol. 1993, 22 (2), 247-252.
2. Panzenbeck, M.; et al. BMY-20014 is a combined Ca++/alpha1-adrenergic antagonist with prolonged effects on coronary blood flow. FASEB J. 1989, 3 (4), 4607.
3. Barrett, R. J.; Wright, K. F.; Allen, A. D.; Taylor, D. R. Cardiovascular and renal actions of AHR-16303B, an antagonist of 5-HT2 receptors and calcium channels, in hypertensive and normotensive rats. J. Cardiovasc. Pharmacol. 1991, 17 (1), 134-144.
4. Walsh, T. Potent dual antagonists ofendothelin and angiotensin II receptors derived from alpha-phenoxyphenylacetic acids (Part III). Bioorg. Med. Chem. Lett. 1995, 5 (11), S1155.
5. Ksander, G.; Savage, P.; Trapani, A.; Balwierczak, J.; Jeng, A. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J. Cardiovasc. Pharmacol. 1998, 31 (Suppl 1), S71-S73.
6. Trapani, A.; De Lombaert, S.; Kuzmich, S.; Leng, A. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11. J. Cardiovasc. Pharmacol. 1995, 26 (Suppl. 3), S69-S71.
7. Trapani, A.; De Lombaert, S.; Beil, M.; Bruseo, C.; Savage, P.; Chou, M.; Jeng, A. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11. Life Sci. 2000, 67 (9), 1025-1033.
8. Trippodo, N.; Robl, J.; Asaad, M.; Bird, J.; Panchal, B.; Schaeffer, T.; Fox, M.; Giancarli, M.; Cheung, H. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J. Pharmacol. Exp. Ther. 1995, 275 (2), 745-752.
9. Fournie-Zaluski, M.; Coric, P.; Thery, V.; Gonzalez, W.; Meudal, H.; Turcaud, S.; Michel, J.; Roques, B. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. J. Med. Chem. 1996, 39 (13), 2594-2608.
10. Ferrario, C. M.; Smith, R. D.; Brosnihan, B.; Chappell, M. C.; Campese, V. M.; Vesterqvist, O.; Liao, W. C.; Ruddy, M. C.; Grim, C. E. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am. J. Hypertens. 2002, 15 (6), 557-564.
11. Norton, G. R.; Woodiwiss, A. J.; Hartford, C.; Trifunovic, B.; Middlemost, S.; Lee, A.; Allen, M. J. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am. J. Hypertens. 1999, 12 (6), 563-571.
12. Hansch, C. Quantitative Structure-Activity Ralationships and the Unnamed Science. Acc. Chem. Res. 1993, 26, S147-S153.
13. Apostolakis, J.; Caflisch, A. Computational Ligand Design. Comb. Chem. High Throughput Screen. 1999, 2 (2), 91-104.
14. Poroikov, V. V.; Filimonov, D. A.; Borodina, Yu. V.; Lagunin, A. A.; Kos, A. Robustness of biological activity spectra predicting by computer program pass for non-congeneric sets of chemical compounds. J. Chem. Inf. Comput. Sci. 2000, 40 (6), 1349-1355.
15. Lagunin, A.; Stepanchikova, A.; Filimonov, D.; Poroikov, V. Internet server for on-line prediction of the biological activity spectrum for a substance. Bioinformatics 2000, 16 (8), 747-748.
16. Anzali, S.; Barnickel, G.; Cezanne, B.; Krug, M.; Filimonov, D.; Poroikov, V. Discriminating between Drugs and Nondrugs by Prediction of Activity Spectra for Substances (PASS). J. Med. Chem. 2001, 44, 2432-2437.
17. Web site: http://www.ibmh.msk.su/PASS.
18. Soffer, R. L. Angiotensin-converting enzyme. In Biochemical Regulation of Blood Pressure; Soffer, R. L., Ed.; Wiley: New York, 1981; pp 123-164.
19. Bakris, G. L. Angiotensin-converting enzyme inhibition to enhance vascular health-clinical and research models. Am. J. Hypertens. 2001, 14 (8, Part 2), 264-269.
20. Pitt, B. The anti-ischemic potential of angiotensin converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial. Clin. Cardiol. 2000, 23 (Suppl. 4), IV9-IV14.
21. Halkin, A.; Keren, G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am. J. Med. 2002, 112 (2), 126-134.
22. Hubner, R. A.; Kubota, E.; Casley, D. J.; Johnston, C. I.; Burrell, L. M. In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. J. Hypertens. 2001, 19 (5), 941-946.
23. Beaumont, A.; Foumie-Zaluski, M.-C.; Roques, B. P. Neutral endopeptidase-24.11: structure, and design and clinical use of inhibitors. In Zinc metalloproteases in health and disease; Hooper, N. M., Ed.; Taylor & France: London, 1996; pp 105-131.
24. Raut, R.; Rouleau, J. L.; Blais, C. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am. J. Physiol. 1999, 276 (5, Part 2), 1769-1779.
25. Duncan, A.; James, C.; Anastopolus, F.; Kladis, A.; Briscoe, T. A.; Campbell, D. J. Interaction between neutral endopeptidase and ACE inhibition in rat with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide level. J. Pharmacol. Exp. Ther. 1999, 289 (1), 295-303.
26. Zhang, X.; Recchia, F.; Bernstein, R.; Xu, X.; Nasjletti, A.; Hintze, T. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutralendopeptidase inhibitors and amlodipine in the treatment in heart failure. J. Pharmacol. Exp. Ther. 1999, 288 (2), 742-751.
27. Nawarskas, J.; Rajan, V.; Frishman, W. H. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Heart Dis. 2001, 3 (6), 378-385.
28. Raizada, V.; Luo, W.; Skipper, B. J.; McGuire, P. G. Intracardiac expression of neutral endopeptidase. Mol. Cell. Biochem. 2002, 232 (1-2), 129-131.
29. Filimonov, D.; Poroikov, V.; Borodina, Yu.; Gloriozova, T. Chemical Similarity Assessment through Multilevel Neighborhoods of Atoms: Definition and Comparison with the Other Descriptors. J. Chem. Inf. Comput. Sci. 1999, 39 (4), 666-670.
30. Web site: http://www.mdli.com.
31. Web site: http://www.chembridge.com.
32. Web site: http://www.asinex.com.
33. Elisseeva, Yu. E.; Orekhovich, V. N.; Pavlikhina, L. V. Properties and specificity of bovine kidney carboxycathepsin (peptidyldipeptidase). Vopr. Med. Khim. 1976, 22 (1), 81-89.
34. Freedland, J.; Silverstein, E. A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am. J. Clin. Pathol. 1976, 66, 416-424.
35. Siems, W.-E.; Heder, G.; Komissarova, N. M. Procedure for the determination of angiotensin converting enzyme. J. Lab. Diagn. 1985, 26, 232-234.
36. Belyayev, N. A.; Kolesanova, E. F.; Baronets, V. Yu.; Annayeva, E. R.; Posdnev, V. F.; Panchenko, L. F. Regarding the role of aminopeptidases in enkephalin catabolism: comparative study of regional distribution of aminopeptidases and enkephalinase A in rat brain. Biokhimiya 1990, 55 (10), 1778-1785.
37. Azaryan, A. V. In Peptidhydrolases of the nervous system and their biological function; Galoyan, A. A., Ed.; Ayastan: Yerevan, Armenia, 1989; pp 8-18.
38. Mumford, R. A.; Strauss, A. W.; Powers, J. C.; Pierzchala, P. A.; Nishino, N.; Zimmerman, M. A. Zinc metalloendopeptidase associated with dog pancreatic membranes. J. Biol. Chem. 1980, 255 (6), 2227-2230.
39. Raid, I. A. Vasoactive peptides. In Basic and Clinical Pharmacology, 8th ed.; Katzung, B. G., Ed.; McGraw-Hill: New York, 2001; p 304.
40. Harrison, J. K.; Pearson, W. R.; Lynch, K. R. Molecular characterization of alpha 1- and alpha 2-adrenoceptors. Trends Pharmacol. Sci. 1991, 12 (2), 62-67.
41. Lagunin, A. A.; Filimonov, D. A.; Poroikov, V. V. Computer-Aided Search for Potential Drugs Exhibiting a Combined Antihypertensive Effect. Pharm. Chem. J. 2001, 35 (7), 375-381.
42. Roques, B. P.; Noble, F.; Daugee, V.; Fournie-Zaluski, M. C.; Beaumont, A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 1993, 45, 87-146.
43. Ruskoaho, H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol. Rev. 1992, 44 (4), 479-602.
44. Turner, A. J.; Tanzawa, K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 1997, 11 (5), 355-364.
45. Corvol, P.; Williams, T. A.; Soubrier, F. Peptidil dipeptidase A: angiotensin I-converting enzyme. In Methods in Enzymology; Barrett, A. J., Ed.; Academic Press: New York, 1995; pp 283-305.
46. Kuleshova, E. F.; Anisimova, O. S.; Sheinker, Yu. N.; Fayermark, I. F.; Schvarz, G. Ya.; Volchenok, V. I.; Evstratova, M. I.; Yakhontov, L. N. Study of the metabolism of the antihypertensive preparation methyopril. Chim. Pharm. J. 1995, 29 (3), 15-18.